Abstract:
Baseline cardiovascular assessment before the initiation of potentially cardiotoxic cancer therapies is a key component of cardio-oncology, aiming to reduce cardiovascular complications and morbidity in patients and survivors. Recent clinical practice guidelines provide both general and cancer therapy–specific recommendations for baseline cardiovascular toxicity risk assessment and management, including the use of dedicated risk scores, cardiovascular imaging, and biomarker testing. However, the value of such interventions in altering disease trajectories has not been established, with many recommendations based on expert opinion or studies with high risk of bias. Advances in understanding underlying mechanisms of cardiotoxicity and the increased availability of genetic and immunological profiling present new opportunities for personalized risk assessment. This paper evaluates existing evidence on cardiovascular care of cancer patients prior to cardiotoxic cancer therapy and highlights gaps in evidence and priorities for future research.
JACC CardioOncology Editor-in-Chief and CME EditorBonnie Ky, MD, MSCE, FACCAuthorNikhil Narang, MD FACC
Important Dates
Date of Release: October 15, 2024Term of Approval/Date of CME/MOC Expiration: October 14, 2025